Two randomized migraine studies of galcanezumab
Effects on patient functioning and disability
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 14, 2018
- Accepted in final form March 14, 2019
- First Published July 3, 2019.
Article Versions
- Previous version (July 3, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Janet H. Ford, PhD,
- David W. Ayer, PhD,
- Qi Zhang, PhD,
- Jeffrey N. Carter, PhD,
- Elizabeth Leroux, MD,
- Vladimir Skljarevski, MD,
- Sheena K. Aurora, MD,
- Antje Tockhorn-Heidenreich, MSc and
- Richard B. Lipton, MD
- Janet H. Ford, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
1) Eli Lilly and Company, Global Health Outcomes Research Scientist, 19 years
NONE
NONE
NONE
NONE
1) Employed by Eli Lilly and Company
NONE
NONE
NONE
1) Eli Lilly and Company, stock/stock options as part of employment compensation Stock/Stock Options, Medical Equipment & Materials: 1) Eli Lilly and Company (galcanezumab), stock/stock options as part of employment compensation
NONE
NONE
NONE
NONE
NONE
- David W. Ayer, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Lilly, Senior Research Scientist, 5 years
NONE
NONE
NONE
NONE
Lilly
NONE
NONE
NONE
NONE
NONE
NONE
Lilly, 5 years Stock/Stock Options, Medical Equipment & Materials: Lilly, 5 years
NONE
NONE
- Qi Zhang, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
At the time of writing this manuscript, I am employee of Eli Lilly and company.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jeffrey N. Carter, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Eli Lilly and Company, 2016-2018
NONE
NONE
NONE
NONE
During the years 2016-2018, I was a full-time employee of Eli Lilly and Company.
NONE
NONE
NONE
As a full-time employee of Eli Lilly and Company from 2016 to 2018, I purchased and currently own minority share of company common stock.
NONE
NONE
NONE
NONE
NONE
- Elizabeth Leroux, MD,
(1) Allergan (2) Novartis (3) Eli Lillly (4) Teva Neuroscience
NONE
NONE
NONE
NONE
NONE
NONE
(1) Teva Neuroscience
(1) Allergan (2) Novartis (3) Eli Lillly
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vladimir Skljarevski, MD,
NONE
NONE
NONE
NONE
NONE
NONE
Full-time employee of Eli Lilly and Company
NONE
NONE
NONE
NONE
Full-time employee of Eli Lilly and Company
NONE
NONE
NONE
NONE
NONE
NONE
Minor shareholder of Eli Lilly and Company
NONE
NONE
- Sheena K. Aurora, MD,
Full time employee of Lilly
Travel reimbursed by Lilly
Lilly
NONE
With Lilly
NONE
Lilly
Lilly
NONE
NONE
NONE
Lilly
NONE
NONE
NONE
Lilly
NONE
NONE
Lilly Stock/Stock Options, Medical Equipment & Materials: Lilly
NONE
NONE
- Antje Tockhorn-Heidenreich, MSc and
NONE
NONE
NONE
NONE
NONE
NONE
Eli Lilly and Company, Limited, Senior Research Scientist Global Patient Outcomes and Real-World Evidence, employed since 2010-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Eli Lilly and Company
NONE
NONE
- Richard B. Lipton, MD
Allergan, e-Neura, Merck
NONE
Serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy?s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta
Neurology, Editorial Board, 2017-
NONE
Wolff's Headache, 8th Edition, Oxford University Press; Informa
NONE
Serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy?s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta
NONE
NONE
NONE
Vedanta Research Migraine epidemiology and Progression June 2010 - present Boston Scientific Occipital Nerve Stimulation in Migraine March 2013 - present ElectroCore Vagal Nerve Stimulation for Migraine and Cluster May 2013 Novartis Sleep and Migraine September 2012 - present Allergan Botox in Migraine April 2012 - present Allergan Chronic Migraine Epidemiology and Outcome Study January 2012 - present
NIH/NIA 2PO1 AG003949 Einstein Aging Study 9/1/16-5/31/21 Role: Principle Investigator NIH R01AG042595 Stress, cognition, repetitive unconstructive thoughts and inflammatory markers 7/1/12-6/30/17 Role: Investigator NIH/NINDS 1U10NS077308-01 Einstein Center for Excellence for Clinical Trials in Neuroscience 9/30/11-8/31/18 Role: Co-PI NIH/NINDS R01 NS082432-03 Brain injury due to soccer heading and opportunities for its mitigation 4/1/13-3/31/18 Role: Investigator NINDS/NIH 1R01AG048642 Study of Latinos-Investigation of Neurocognitive Aging 9/1/15-4/30/17 Role: Co-Investigator 1K23NS096107-01 Clinical Decision Support for Patient Migraine Management 4/01/16-3/31/21 Role: Primary Mentor 1K23AG049466-01 The relation of migraine to daily hormone patterns and menopausal stage 9/30/16-5/31/17 Role: Primary Mentor 1K01AG054700-01 Application of latent and integrative approaches to understand the spectrum of cognitive aging 3/15/17-2/28/22 Role: Primary Mentor
NONE
S & L Marx Foundation Alzheimer's Research Czap Foundation Alzheimer's Research
eNeura Pharma; Biohaven Inc.
NONE
Oxford University Press; Baxter Publishing
NONE
NONE
NONE
- From Eli Lilly and Company (J.H.F., D.W.A., V.S., S.K.A., A.T.-H.), Indianapolis, IN; Sanofi (Q.Z.), Bridgewater, NJ; Elanco (J.N.C.), Greenfield, IN; Department of Neurology (E.L.), University of Calgary, Canada; and Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY.
- Correspondence
Dr. Ford ford_janet{at}lilly.com
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.